Primary biliary cirrhosis,
sometimes called primary biliary cholangitis, is a chronic liver disease that
damages tiny bile ducts in the liver by causing inflammation, fibrosis, and
bile duct blockage. Autoimmunity, infection, and/or genetic predisposition are
possible causes of primary biliary cirrhosis. Itching, osteoporosis, high blood
cholesterol, and malabsorption of fat and fat-soluble vitamins are all signs of
primary biliary cirrhosis. These symptoms can progress to hepatomegaly,
hyperpigmentation, splenomegaly, jaundice, sicca syndrome, or Kayser-Fleischer
rings. In its latter stages, primary biliary cirrhosis can lead the liver to
shut down altogether.
The Primary
Biliary Cholangitis Treatment Market is anticipated to grow as a
result of more pipeline research being conducted to create effective treatments
for uncommon illnesses like the condition. For instance, CymaBay Therapeutics,
Inc. began a phase 3 clinical study for seladelpar 5-10mg in October 2018 under
a placebo-controlled and randomised design. Seladelpar's safety and
effectiveness in treating patients with primary biliary cholangitis (PBC) was
evaluated in this trial, along with the patients' receptivity to or intolerance
to ursodeoxycholic acid (UDCA). December 2021 is the projected completion date
for the research. The global
primary biliary cholangitis treatment market size was valued at US$
526.4 million in 2017, and is expected to witness a CAGR of 36.3% during the forecast period (2018 – 2026).
Moreover, GlaxoSmithKline (GSK)
began a phase 2 clinical research in January 2017 to investigate the
effectiveness, safety, and tolerability of administering GSK2330672 for the
treatment of pruritus (itch) in individuals with primary biliary cholangitis
(PBC). Due to increasing efforts by industry participants to provide
cutting-edge treatment options for PBC, North America is predicted to see
profitable primary biliary cholangitis treatment market expansion. For
instance, the TARGET-PBC (Primary Biliary Cholangitis) platform was introduced
in October 2016 by the US company TARGET PharmaSolutions, Inc. in partnership
with Intercept Pharmaceuticals, Inc. The TARGET-PBC platform was developed to
enhance our comprehension of actual therapy patterns for PBC.
Comments
Post a Comment